A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

NCT00001021 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: rgp120/HIV-1IIIB
BIOLOGICAL: rgp120/HIV-1MN

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]